• SRAX’s performance goes from strength to strength; company announced revenue guidance expecting revenues of $11.5 million for the first quarter and full-year revenues of $46M – $48M.
• Company’s SaaS platform Sequire expected to continue to drive growth and remain instrumental to performance.
• As go-to data provider for investors and public companies, SRAX stays committed to innovating on product, sales, and marketing, which all translates into increased revenue.

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies, has announced revenue guidance for 2022, anticipating another strong period ahead. The company expects revenues of $11.5 million for the first quarter, a 111% increase over Q1 2021 revenue. The full-year revenues are expected to be $46M – $48M, an increase of 46% – 52% over 2021 unaudited revenue of approximately $31.5M. In addition, the company announced that the Q4 2021 booking meets expectations (https://ibn.fm/PJKY8). With solutions built to bring clarity and make the digital space more transparent, SRAX aims to deliver unbiased data and reveal analytics for companies to manage ROI from investor relations programs and corporate communication firms. The company’s growth remains closely linked to Sequire, its SaaS platform. Last year the platform grew both in subscribers and functionality, resulting in considerable revenue growth and customer renewals. This year Sequire has a number of significant releases that will continue to enhance the platform’s value. Sequire’s success is driven by its focus on delivering solutions that solve important pain points for public companies. To stay competitive in today’s environment, companies need to better communicate with their shareholders and the broader investment community. As a data analytics platform designed for public companies to track essential data, SRAX provides unique opportunities for investors and public companies to connect and communicate through its Sequire SaaS platform. Sequire provides users with data that help them understand market activity and develop insights to engage their investor base. With this platform, companies can track their investors’ behaviors and trends and use those insights to engage current and potential investors across marketing channels. SRAX has also expanded its model to include additional value-added services from the investor relations space, such as their preeminent industry conferences. The company owns LD Micro, a respected conference provider targeted at small and micro-cap markets. “Our team did excellent work in 2021, meeting and exceeding our guidance. The nature of our annual contracts provides us exceptional visibility into revenue,” said Christopher Miglino, Founder and CEO of SRAX. “We are projecting that we will have our largest quarter ever in Q1 of 2022. With an acceleration in sales at the end of Q4, we are very comfortable in providing a full-year, 2022 guidance of $46-$48M,” added Miglino. SRAX has seen its financial performance go from strength to strength over the past year, with recently reported results revealing exceptional revenue growth. Its remarkable performance and growth trajectory appear to have contributed to the increased investors’ interest, with several hedge funds and other institutional players adding to their stakes in the company (https://ibn.fm/J6IAL). For more information, visit the company’s website at www.SRAX.com. NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Over 466 million people current suffer from disabling hearing loss with a further 1.1 billion people at risk of suffering hearing damage
• Elevated device cost, poor after-sales service, and a lack of access to proper healthcare have led to only 14% of the 48 million American with hearing loss to currently use hearing aid devices
• InnerScope Hearing Technologies has sought to address this issue with its affordable direct-to-consumer sales model
• InnerScope CEO, Matthew Moore presented at the Emerging Growth Conference on January 5th, updating shareholders and investors on the company’s latest operational highlights

As of March 2019, the World Health Organization (“WHO”) estimated that disabling hearing loss affected around 466 million people across the globe, out of whom 34 million were children. Moreover, the WHO forecast that up to 1.1 billion people between the ages of 12 to 35 years globally were subject to hearing loss risk, largely due to constant noise exposure (https://ibn.fm/ftcaw). InnerScope Hearing Technologies (OTC: INND), a manufacturer and distributor/retailer of DTC, FDA registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (“PSAPs”), has long sought to become a leader in the direct-to-consumer hearing aid market, with the goal in mind to provide affordable hearing to the tens of millions of Americans suffering from hearing loss today. Elevated device costs, problems associated with devices such as post-purchase services, battery problems, and maintenance issues, along with poor access to adequate healthcare, are all factors that have historically contributed towards restricting the growth of the global hearing aid market. In fact, a recent White House Fact Sheet revealed that the elevated cost of hearing aids had led to only 14% of the approximately 48 million Americans with hearing loss using them (https://ibn.fm/pEwQI). In addition, a heavily concentrated marketplace – with the four largest hearing aid manufacturers controlling upwards of 84% of the market – has also contributed to the elevated pricing for the devices. Nonetheless, the global hearing aid market is estimated to display a strong underlying growth trend over the coming years, with a forecast 6.6% CAGR between 2021-2028. Through its dedicated online portal, www.iHeardirect.com, InnerScope has looked to provide consumers with affordable, Bluetooth app-controlled, self-adjusting hearing technology in a prompt and affordable manner. The company’s HearIQ App for iPhone and Android has been designed to include a free self-check hearing test, providing billions of people worldwide with the means to detect and self-diagnose early-onset hearing loss. Meanwhile, the company’s proprietary hearing technology provides customers with the ability to personalize each hearing device to their hearing needs in under 10 minutes. InnerScope Hearing Technologies recently acquired HearingAssist, a long-established leader in the direct-to-consumer hearing aid market and Walmart’s largest hearing aid supplier, for a gross consideration of $10 million, with the express intent to create a “powerful disruptive company in the global hearing device market.” At the time of acquisition, Matthew Moore, President and CEO of InnerScope, stated, “Today is a tremendous milestone for InnerScope. I’m delighted to welcome the HearingAssist team, who share our passion for providing convenient and affordable hearing products for the tens of millions of Americans who suffer from hearing loss. The HearingAssist acquisition is another meaningful step in advancing our strategy to grow as a leader and innovator in the direct-to-consumer hearing aid market.” Separately, InnerScope Hearing has revealed that Matthew Moore was invited to present at the Emerging Growth Conference, a live interactive online event that took place on Wednesday 5^th January, which allowed InnerScope’s existing shareholders and the investment community to interact with InnerScope’s CEO in real-time. Interested investors. You can watch Moore presentation by clicking on the link: https://www.youtube.com/watch?v=QuAndXZLbMk Moore’s presentation highlighted InnerScope’s two recent direct-to-consumer hearing aid company acquisitions with iHear Medical Inc., its 40+ patents, and its iHearTest, the only FDA-cleared, in-home hearing test on the market and sold at CVS Pharmacy’s; and HearAssist II LLC., Walmart’s largest hearing aid supplier. In addition, Moore discussed InnerScope’s 2022 growth trajectory with these pivotal acquisitions and a key partnership with Atlazo Inc., a leader in intelligent semiconductor solutions, to develop new types of unprecedented artificial intelligence hearing products. For more information, visit the company’s website at www.INND.com and the company’s e-commerce websites www.iHeardirect.com and www.HearingAssist.com NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• President and CTO Dean Rositano was invited to be a new member of the prestigious Rolling Stone Culture Council – an invitation-only network of leaders who are on the cutting edge of culture, community, and the Rolling Stone brand
• Artist Republik will join Fan Pass Live as a Friendable Company, increasing the number of artists on the platform
• CEO and Co-Founder Robert Rositano Jr. explained that one of the company’s main goals has always been to test multiple entry points to gain exposure in the music industry for artists and fans alike

Mobile technology and marketing company Friendable (OTC: FDBL) has achieved several important milestones throughout 2021 and has big things planned for the new year as well, focusing mostly on further scaling its Fan Pass Live artist streaming platform offering and expanding its industry relationships. Taking one step closer to achieving the latter, the company announced that President and CTO Dean Rositano was invited to be a part of the prestigious Rolling Stone Culture Council (https://ibn.fm/lbXDe). The Council is an invitation-only network of leaders who are on the cutting edge of culture, community, and all it takes to be associated with the Rolling Stone brand. Mr. Rositano was invited to be a part of this community because of his contributions to the music, entertainment, and technological industries. This includes his successful development of automated solutions, services, and technology that enable artists to take true ownership and control over their music and careers. Mr. Rositano has the honor of joining senior leaders from across North America and Europe in music, art, technology, fashion, gaming, media, sports, and entertainment. “Mr. Dean Rositano is an inspiring leader, and we value the knowledge and experience he brings to this community,” Council Co-Founder Scott Gerber said. “The Council brings together members with the right mix of expertise, passion, and energy to do great things. Individuals, businesses, and industries all benefit from the learning and collaboration happening inside.” The announcement follows another major milestone that was recently announced by the company: the closing of the acquisition of Artist Republik, a reputable music distribution company (https://ibn.fm/4fIiX). Following the acquisition transaction completion, Artist Republik is now officially a Friendable Inc. company alongside Fan Pass Live. The new acquisition will add approximately 100,000 artists to the platform and triple the technology deck. The acquisition comes after approximately one year of talks and negotiations between the two companies to seal a partnership, as Artist Republik was moving toward the development of livestream services and Fan Pass was moving toward its own music distribution offering. According to CEO Robert Rositano Jr., Friendable was also able to retain the Artist Republik CEO and CTO as initial consultants after the acquisition, assisting with integration efforts and expanding the service offering. Artists will also receive more autonomy and freedom over their music, ticketed streams, blog/social promotions, exclusive merchandise development, sales, and more. All of this is available to artists without the requirement to give up their musical rights. Friendable also provided the public and its shareholders with a summary of milestones for 2021 and the plans made for 2022. The company has come a long way since its flagship offering, Fan Pass Live artist streaming platform, was released in July 2020, with 16 artists performing live on the platform at the time of the launch. In February 2021, the platform set a record for artist signups, reaching over 350% growth compared to the previous month, including 100% growth in livestream events. By July 2021, when an updated version with new features and options was released, the platform had surpassed 5,000 artist members. In a company press release detailing achievements and strategies, Rositano Jr. thanked all artists members, fans, partners, supporters, team, and shareholders (https://ibn.fm/ysLxn). “We would not be here without each and every one of you pulling for us, and the progress certainly shows we are on the correct path,” he said. Rositano Jr. also said new service offerings will be announced soon as the company expands into various channels of music distribution, working towards the same goal of scaling revenues, number of artists and fan subscribers on the platform. For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL

MSLs are critical in ensuring that products are used efficiently throughout their lifecycle. They serve as scientific peers and resources within the medical community, and provide valuable expertise to internal colleagues. MSLs, like the rest of the life science industry, must quickly adapt to the introduction of new technological platforms and rethink their workload in the post-COVID era. DGE will cordially welcome many professionals to attend the 2nd annual Next-Gen MSL Excellence Symposium, the only industry event dedicated to conquering the daily problems that this critical group faces while achieving career milestones and adjusting to new technology! This symposium is the only virtual industry event dedicated to the work problems encountered by MSLs, emphasizing the relevance of their role in drug and device development as well as adjusting to new technologies in the post-COVID era. Why Should You Attend It?

• Strategies for outlining and achieving professional objectives
• A guide for developing the leadership qualities to advance in your career path
• Key methods for enhancing KOL engagements by honing communication and soft skills.
• Techniques for collaborating well with cross-functional teams and participating in strategic planning
• Innovative ways to use artificial intelligence and social media to gather information and impact medical policy
• Learning and networking with field medical professionals and industry leaders in an interactive online platform

DGE’s 2nd Next-Gen MSL Excellence Symposium will provide a dynamic platform for medical industry KOLs and decision-makers to share their perspectives and discuss the role of MSLs in the changing landscape. They will also provide valuable tips and techniques for building a successful career and demonstrating the value of their skills to the company. This conference is also a fantastic chance for talented individuals interested in pursuing a successful MSL career. Medical Affairs personnel will contact teams that conduct similar duties in order to gain new and expanded ideas and roles. For more information, visit https://ibn.fm/aHMOd.

• Hollywall owns the rights to and music recordings of more than 17,500 songs, in addition to the rights to 29 video games and a film
• As of December 2019, the company’s music library was valued at $146 million
• The music industry has witnessed an upsurge in music catalog acquisitions by investment and management firms and leading music companies
• Hollywall is led by Chairman and CEO Darnell Sutton, who brings years of experience as well as numerous talents as a seasoned professional within the music recording, television production and broadcasting, sports and music celebrity management, and film distribution segments

The 2010s saw an upsurge in music catalog acquisitions, a trend that only accelerated into the 2020s. Describing this “catalog acquisition frenzy,” a January 2021 Rolling Stone Magazine article observed that even investment and management firms and Wall Street companies had entered into the music business by buying rights to famous musicians’ creative works (https://ibn.fm/UCEZK). “Right now, the gorillas in this jungle include Larry Mestel’s Primary Wave and Merck Mercuriadis’s Hipgnosis Songs Fund, two investment and management firms: in 2021 alone, the latter company acquired copyrights and/or income streams from Neil Young, Lindsey Buckingham of Fleetwood Mac, Shakira, and Jimmy Iovine,” reads the article. “This isn’t the first time in recent memory that Wall Street mammoths have gotten involved in the inner workings of the music business,” the article continues. “In 2016, BlackRock (a company with $7.8 trillion in assets under management) led a $300 million investment into Primary Wave – money that was subsequently spent on legendary music catalogs like Bob Marley’s.” Leading music companies such as Warner Music Group and Universal Music Group have also splurged tens of millions of dollars on music catalogs. The logic behind such acquisitions is simple. Firstly, master recordings earn revenue through various avenues, namely sampling, streaming and purchases/downloads, public broadcast, and use in television, film, and commercials. Secondly and according to a 2020 Variety Magazine article, “Publishing assets are currently running at multiples well over 12 with master rights slightly lower but increasing in value… In five to 10 years, it might be 20x – the value continues to rise” (https://ibn.fm/OBLpT). Notably, the market multiple analysis is a valuation approach that applies an EBITDA multiple or Net Publisher’s Share (“NPS”)/Net Label’s Share (“NLS”) multiple based on recent precedent acquisitions. It is used to derive a catalog’s implied market value (https://ibn.fm/Mjfe2). The increasing interest in music catalogs and their projected rise in value bodes well for Hollywall Entertainment (OTC: HWAL), an entertainment, media, infrastructure, telecommunication, technology, and broadcasting company that operates through various subsidiaries. The company, which serves some of the finest creators, writers, developers, and music artisans of our time by offering a business solution and distribution platform that maximizes a global audience reach, wholly owns an extensive music and entertainment library. Hollywall’s asset portfolio includes copyrights, legal rights, trademarks, and master recordings of over 17,500 songs, one of the largest master recording libraries globally. This library features hit songs from the likes of Michael Jackson, Elvis Presley, The Jacksons 5, Marvin Gaye, Dolly Parton, Frank Sinatra, The Who, Bob Marley, Quincy Jones, James Taylor, and more. In addition, HWAL owns the source code, rights, and trademarks of 29 video games and the rights to a film titled ‘The Elvis I Knew.’ With a fair value of about $146 million as of December 31, 2019, according to an intangible asset valuation prepared by Sun Business Valuation and available on the HWAL’s website (https://ibn.fm/3SdFe), Hollywall’s master recordings are only bound to increase in value as time progresses, positioning HWAL for growth well into the future. Led by Chairman and CEO Darnell Sutton, who brings years of experience as well as numerous talents as a seasoned professional within the music recording, television production and broadcasting, sports and music celebrity management, and film distribution segments, Hollywall is favorably poised as one of the entertainment industry’s most exciting companies. For more information, visit the company’s website at www.Hollywall.com. NOTE TO INVESTORS: The latest news and updates relating to HWAL are available in the company’s newsroom at https://ibn.fm/HWAL

• Delic Holdings Corp is a leader in new medicines and treatments for a modern world, with a business network which includes psychedelic wellness clinics, a licensed psilocybin research lab, a famed psychedelic wellness event, and dedicated media platforms
• The company announced that its co-founder and CEO, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference on January 10-13, 2022

Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has long been known for its role as a trailblazer in improving access to health benefits across the country and reframing the conversation on psychedelics. Delic announced that the Company’s Co-founder and Chief Executive Officer, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference, held in an entirely virtual format from January 10-13, 2022. In addition to carrying out one-on-one meetings throughout the course of the conference, Mr. Stang made a corporate presentation on Delic Corp’s expansion strategy and overall industry outlook for the general public. H.C. Wainwright & Co., a full-service investment bank dedicated to providing investment banking, equity research, sales and trading, as well corporate access and strategic advisory services, celebrated 150 years of service in 2018. The firm has gained a well-deserved reputation for its innovative conference line-up over the years, having recently hosted events on topics as varied and diverse as psychedelics, mining, precision oncology, hepatitis B, ophthalmology, cryptocurrencies, blockchain technology and applications, and many more. The H.C. Wainwright Bioconnect Conference, hosted by former FDA commissioner Dr Scott Gottlieb, has sought to bring together a carefully curated collection of cutting-edge biopharmaceutical firms alongside institutional investors, private equity firms, venture capitalists, and industry executives. According to the National Institute of Mental Health, over 17 million Americans have at least one major depressive episode every year, and up to 30% of them receive insufficient help from current medical treatments. Meanwhile, a further estimated 40 million adults struggle with anxiety disorders. In a move towards addressing the growing health crisis in 2018, the FDA moved towards granting psilocybin “breakthrough therapy” status for the treatment of severe depression. Shortly thereafter, first Denver and then Oakland voted to decriminalize the use of psilocybin mushrooms, with the state of California currently reviewing a bill to decriminalize a wide variety of psychedelics (https://ibn.fm/Bu2g4). With the sector on the cusp of broad-based legalization, the psychedelic wellness market is now projected to grow to a size of $10.75 billion by 2027, up from $4.75 billion in 2020 with a forecast CAGR of 12.36 percent over the period of 2021-2027 (https://ibn.fm/jFEPL). Delic has sought to capitalize on the sector’s growth as well as rising demand for psychedelic products and services through the expansion of its proprietary Ketamine Wellness Centers (“KWC”), the largest chain of psychedelic wellness clinics in the country, with 15 more clinics opening in the next 18 months. Delic has also looked to expand its footprint within the sector through its other related businesses, which include Delic Labs, the sole entity currently licensed by Health Canada to focus exclusively on research and development of psilocybin vaporization technology; Meet Delic, the world’s largest psychedelic wellness event; as well as media platforms, Reality Sandwich and Delic Radio. For more information, visit the company’s website at www.DelicCorp.com and the Meet Delic conference website at www.MeetDelic.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Company marked host of major milestones and accomplishments in 2021
• Approvals, licenses, expansions and growth all essential pieces of Cybin success
• CYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022

As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off big last year, with the company marking a host of major milestones and accomplishments and looking toward more of the same for 2022. “2021 was an exciting year for Cybin,” said Cybin CEO Doug Drysdale. “We expanded our organization from five to more than 55 employees across four countries and have established an operating ecosystem of nearly 50 partners and vendors that have supported more than 90 preclinical studies and numerous patent and investigational new drug filings over the past 12 months.” And that’s just the beginning for the emerging leader in the psychedelics industry. The company points to several key highlights this past year as proof positive it is on the right road to psychedelic success. Ranking at the top of 2021 milestones were the notice of allowance awarded from the U.S. Patent and Trademark Office for Cybin’s CYB004 (deuterated psychedelic tryptamine) for the treatment of anxiety disorders and FDA approvals for the company’s cofunded investigator-initiated phase 2 clinical trial. Using the EMBARK psychedelic facilitator training program, the trial is designed to evaluate psychedelic-assisted psychotherapy to treat frontline clinicians experiencing COVID-related distress. In addition, company leaders confirmed a scientific advice meeting with the UK’s Medical and Healthcare Products Regulatory Agency regarding CYBN’s lead candidate CYB003 for the treatment of major depressive disorder and alcohol use disorder. Cybin also announced positive CYB003 data showing significant advantages compared to oral psilocybin for the treatment of mental health disorders, including a 50% reduction in variability, a 50% reduction in dose, a 50% shorter time to onset and nearly double brain penetration. Other 2021 highlights for Cybin included receiving a grant for a psychedelic treatment clinic at Lenox Hill Hospital, part of the largest healthcare system in New York State, to benefit underserved communities; being granted a schedule I manufacturing license from the U.S. Drug Enforcement Agency for its Boston-area research lab, which will allow the company to expand its internal R&D capabilities; receiving approval from the FDA for its investigational new drug application to proceed with a company-sponsored feasibility study using the Kernel Flow quantitative neuroimaging technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics; and the completion of 74 in-vitro and in-vivo evaluations of the company’s expanding portfolio of psychedelic compounds being designed for potential therapeutic applications for several mental health conditions. There were many more 2021 highlights for Cybin, which expanded operations into Europe and was the first psychedelic company to list on the NYSE American market. “Driven by promising and differentiating preclinical data, our innovative operational and R&D pipeline platforms expect to support four first-in-human clinical studies in 2022, which we hope will progress our proprietary psychedelic development candidates CYB003 and CYB004 closer toward potential approval for treating depression and addiction disorders,” Drysdale stated. “We believe 2022 will be a truly transformative year for Cybin.” Cybin is a leading ethical biopharmaceutical company on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development
• He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year
• Mr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly better than what is available in the market
• Going into 2022, Mydecine will embark on more clinical studies on smoking cessation and PTSD, focus more on novel compound production and growing its Mindleap digital health platform

Josh Bartch, the Co-Founder, Chairman, and Chief Executive Officer (“CEO”) of Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA), recently appeared on The Bell2BellPodcast, a platform meant to highlight key organizations, leaders and entrepreneurs who are leaving a mark in their respective industries. Mr. Bartch briefly shared his background, leading up to co-founding Mydecine, along with the goals for the company for the new year. Of note was Mydecine’s phased approach, which Bartch noted is integral to the company’s operations, along with its future. “Mydecine Innovations Group…is really focused on first- and second-generation novel therapeutics derived from different psychedelic molecules. We’re using those as a blueprint or starting point and then making several improvements for what we call second-generation psychedelic molecules for the treatment of a number of indications,” Bartch noted (https://ibn.fm/kLsnW). So far, Mydecine addresses two lead indications- smoking cessation and PTSD. In 2021, the company partnered with Johns Hopkins University (“JHU”) for further research on smoking cessation and has so far made some significant strides in PTSD treatment. In addition, its phased approach, which entails understanding the imperfections of initial formulations and then modifying them to make them more effective, has already set the company apart from its peers. As a result, the first generation of products is already proving significantly better than what is currently available in the market. “For smoking cessation, for instance, you’re looking at no good solutions currently available,” noted Mr. Bartch. “You have Chantix, which was recently recalled for a cancer-causing carcinogen…Even before, when it was still available on the shelf, this is a blockbuster drug doing $1.2 billion per year with efficacy data in the single digits at 12 months,” he added. With what Mydecine is offering, Bartch noted, early-stage trials have proven to be way better than what was available in the market. Efficacy data has shown upwards of 80% in six months and 67% at 12 months, all attributed to its phased approach. “Through our phased approach, we take that first generation, look at imperfections and make improvements- things in the nature of half-life, controllability delivery time, onset time, anxiety associated with different molecules, etc.,” Bartch reckoned. Going into 2022, Mr. Bartch was keen to note that Mydecine will start two clinical trials- a smoking cessation study and a PTSD Phase 2a study. He also noted the company’s commitment to focusing more on novel compound production and getting them to clinics around the country, which will also be accompanied by publishing pre-clinical results following the studies carried out so far. 2022 will also be the year when Mydecine commercializes its Mindleap digital health platform, as it focuses on growing the number of its users and further improving its offering. To listen to the whole podcast, please visit https://ibn.fm/JQwe2 For more information, visit the company’s website at www.Mydecine.com. NOTE TO INVESTORS: The latest news and updates relating to MYCOF are available in the company’s newsroom at https://ibn.fm/MYCOF

• Mineral property exploration company StraightUp Resources enters 2022 with a new CEO, the tailwind from a new OTCQB Market listing, DTC Eligibility, and encouraging reports on its properties and neighboring properties owned by other companies
• As Americans shift their focus from COVID policies to inflationary pressures and other economic matters, many investors are mulling the appeal of precious metals as a safe haven
• StraightUp holds a mine in the historically productive Bullfrog mining district in Southern Nevada
• The company also holds options for five potentially productive greenbelt sites in Ontario, which the company is assessing

As Americans weary of COVID-19 pandemic restrictions and worry more about the economy and inflations’ effects on their personal finances (https://ibn.fm/zvg2o), many investors are considering a move toward precious metals as a safe haven (https://ibn.fm/PpcPM). Despite recent negative perceptions about gold values, “The December-January period is historically very strong for bullion, which has gained in 8 out of the last 10 Januaries,” a senior investment analyst at brokerage XM recently stated (https://ibn.fm/agG3q). StraightUp Resources (CSE: ST) (OTCQB: STUPF), a company dedicated to acquiring and exploring precious metals resources, is optimistic about the potential of the precious metals market in light of the uncertainty in economic forces at play in the world today. The Canadian company is focusing most of its attention on five projects it has optioned in Ontario’s greenbelt region. The Ferdinand, RLX North and RLX South, Belanger and Bear Head Gold projects sit astride 21,087 hectares (52,107 acres) of potential productivity in a zone already known for gold output topping 30 million ounces. Airborne magnetic surveys (“MAG”) have been completed on three of StraightUp’s properties, and some ground exploration has begun. The company is also enthused about a United States mine property acquired last year in the historically gold-productive Bullfrog region around Beatty, Nev. — particularly in light of news that South African gold major AngloGold Ashanti has upped its investment in the premier mining jurisdiction by buying out Corvus Gold’s shares in order to acquire other Bullfrog region properties (https://ibn.fm/lMWus). StraightUp Resources is similarly encouraged by the potential for stockholder optimism after Kinross Gold Corp. announced last month a definitive agreement with Great Bear Resources Ltd. to buy the company and its holdings, including Red Lake District property neighboring StraightUp’s Ferdinand Gold Project in Ontario (https://ibn.fm/4g505). The company’s international aspirations also led it to contemplate the potential acquisition a silver mine and processing plant in Peru through a right of exclusivity agreement (“ROE”) for all outstanding shares in Premier Silver Corp. that the company announced in October. The ROE had an expiration date in late December if it was not fulfilled, however, and StraightUp ended the year without completing any new acquisitions or business relationships that had not been previously announced, according to a recent monthly progress report (erroneously dated 2021) (https://ibn.fm/mxDyP). In order to build on the company’s potential going into 2022, experienced entrepreneur and economic geologist Rod Husband was named the company’s new CEO in December while former CEO Mark Brezer tightened his focus on his duties as president and director (https://ibn.fm/k6qwp). “We are excited to have Mr. Husband’s calibre of leadership and operational experience on board, especially during this phase of the Company’s growth and expansion into international markets. This appointment strengthens management and brings a new layer of expertise to the team,” Brezer stated in the announcement. The company upgraded to the OTCQB Venture Market in the United States to improve its access to investors, and on Jan. 10 announced a non-brokered private placement to raise additional funding (https://ibn.fm/k74QQ). For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• In August, GreenBox celebrated a monumental milestone when it processed over $1 billion in transaction volume for all of 2021
• GreenBox’s year-to-date processing volume grew to $1.4 billion as of September 30, 2021
• The company reported $8 million in revenue and $5.6 million in gross profit in Q3 2021
• GreenBox appointed Paul Levine as CEO and Co-Founder of Coyni stablecoin spinoff company, Robert Houghton as CTO, and Jacqueline Reynolds as CMO
• The company’s management hosted a year-end update call on December 9

Approximately eight months after GreenBox POS (NASDAQ: GBOX) released its Generation 3 (“Gen3”) technology, which expanded and expedited the process of onboarding, monitoring, and controlling merchant portfolios in its proprietary blockchain-based platform, the company crossed a significant milestone – the processing of more than $1 billion in transaction volume in 2021. The milestone represented about five times the total processing volume recorded in 2020 (https://ibn.fm/IwNLS). Attributable to the Gen3 technology, expansion of its ISO and agent network, and the acquisitions of ChargeSavvy and Northeast Merchant Services, the monumental milestone demonstrated GreenBox’s successful development and deployment of its one-of-a-kind blockchain ledger-based payment processing technology. These factors would again play a significant role in growing the transaction volume figures even further as detailed in a November 11 news release detailing the financial results for the three months ended September 30, 2021 (“Q3 2021”) (https://ibn.fm/GzOeP). GreenBox noted it had processed a quarterly record of $540 million, which contributed to a year-to-date volume of $1.4 billion as of September 30, 2021. Notably, this Q3 2021 transaction volume had grown roughly 1,400% compared to a similar period a year earlier. Other key highlights included a 163% year-over-year (“YoY”) increase in quarterly net revenue from $3.0 million in Q3 2020 to $8.0 million in Q3 2021. Sequentially, the net revenues increased by 26% quarter over quarter (“QoQ”) from $6.4 million recorded in Q2 2021. At the same time, gross profit in Q3 2021 stood at $5.6 million (69.5% of total revenue), compared to $1.2 million (39.6% of total revenue) in Q3 2020 and $5.1 million (79.3% of total revenue) in Q2 2021. Additionally, the company fortified its balance sheet upon securing a $100 million convertible note financing. The fund will go toward supporting its acquisition strategy, adding money to its Coyni stablecoin revolver to grow it up to $25 million, and additional technology development. GreenBox also engaged in revenue sharing and licensing cooperation with Transact Europe enabling it to leverage key licensing assets and recognize processing volume. “Our third quarter of 2021 was instrumental in building the foundation for 2022 and beyond. We continued to successfully execute on our long-term growth strategy of quickly scaling our processing volume while accumulating licensing assets through select acquisitions and partnerships,” commented GreenBox CEO Fredi Nisan. “Despite all GreenBox has accomplished in the last 18 months, we are still just in the early innings of scaling our technology. We remain confident in our long-term strategy and are well positioned to capitalize on the opportunity at hand.” Fredi underlined that the company expects to grow its processing volumes and exceed its initial 2021 guidance of $1.85 billion. Further, GreenBox expects 2021 reported revenue of at least $28 million and adjusted net income of at least $8 million. The third quarter also saw several additions to the company’s management team. GreenBox appointed Paul Levine, a technology innovator and former President of Planet Payment, as CEO and Co-Founder of the Coyni stablecoin spinoff company (“SpinCo”), as it lays the groundwork for the eventual public offering of Coyni. Additionally, the company hired Robert Houghton as the Chief Technology Officer. In this role, Robert will lead GreenBox’s payment technology roadmap as well as ensure efficient integration of acquisitions. On November 16, the company announced the appointment of marketing guru Jacqueline B. Reynolds as its new Chief Marketing Officer (“CMO”). A world-class global marketer, she has launched massive campaigns while working with household names such as Coca-Cola (NYSE: KO), McDonald’s (NYSE: MCD), Verizon (NYSE: VZ), Walmart (NYSE: WMT), L’Oréal, Xbox,  7-Eleven, and other Fortune 500 companies. She has also held senior leadership positions at global brands, top agencies, and media companies, spearheading award-winning programs with international partners. “As CMO, Jacqueline will lead all marketing strategy, including the development of GreenBox’s brand positioning, along with a communications plan to relevantly connect with customers and investors, focused across a variety of platforms,” explains the November 16 news release. Paul Levine and Jacqueline Reynolds joined several other key members of the company’s management, including GreenBox Chairman Ben Errez and Fredi Nisan, in a year-end corporate update call hosted on December 9 (https://ibn.fm/YrkxB). A recording of the call is available via https://ibn.fm/tVbrz (registration required), with a transcript available here https://ibn.fm/kihii. GreenBox is an emerging financial technology enterprise leveraging proprietary blockchain security and token technology to develop customized payment solutions. Guided by the mission to build compliant cutting edge blockchain ledger tokenized payment solutions for the diverse, evolving, and dynamic global market, the company operates along four pillars – card-issuing, payment processing, Coyni stablecoin, and banking-as-a-service. For more information, visit the company’s website at www.GreenBoxPOS.com. NOTE TO INVESTORS: The latest news and updates relating to GBOX are available in the company’s newsroom at https://ibn.fm/GBOX